Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan

Abstract

A large proportion of Muslim patients with type 2 diabetes mellitus (T2DM) elect to fast during the holy month of Ramadan. For these patients hypo- and hyperglycemia constitute two major complications associated with the profound changes in food pattern during the Ramadan fast, and efficacious treatment options with a low risk of hypoglycemia are therefore needed to manage their T2DM as effectively and safely as possible. Dipeptidyl peptidase-4 (DPP-4) inhibitors modulate insulin and glucagon secretion in a glucose-dependent manner, and consequently a low propensity of hypoglycemia has consistently been reported across different patient populations with these agents. Promising data with DPP-4 inhibitors have now also started to emerge in patients with T2DM fasting during Ramadan. The objective of this review is to provide a comprehensive overview of the currently available evidence and potential role of DPP-4 inhibitors in the management of patients with T2DM fasting during Ramadan whose diabetes is treated with oral antidiabetic drugs, and to discuss the mechanistic basis for their beneficial effects in this setting.

Keywords:

• dipeptidyl peptidase-4
• incretin
• type 2 diabetes mellitus
• hypoglycemia

Acknowledgments

The authors gratefully acknowledge Anuja Shah (Novartis Healthcare Pvt Ltd) for technical help.

Disclosure

Anja Schweizer and Sylvie Dejager are employed by Novartis and own shares. Serge Halimi has received fees for consultancy, advisory boards, speaking, clinical studies, travel or accommodation from Novo-Nordisk, Lilly, Sanofi, Novartis, Boehringer Ingelheim, MSD, BMS, Astra-Zeneca, and Roche. The authors have no other conflicts of interest in this work.